•  
  •  
  •  
  •  

2025-10-02 01:48:58

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue

Keywords Selected:  VenusRemedies

Stock Report

  • Venus Remedies Ltd receives GMP certification from Moldova
  • Venus Remedies Secures Marketing Authorization in Philippines
  • Venus Remedies Ltd approves formation of subsidiary in Hungary
  • Venus Remedies Expands Reach in ASEAN Region with Malaysian PIC/S GMP Approval for Pre-Filled Syringe Facility
  • Venus Remedies Clinches WHO-Backed PAHO tender, takes its global fight against Cancer to next level
  • Venus Remedies achieves major milestone with UNICEF
  • Venus Remedies Ltd receives Rs. 2.50 crore under PLI scheme
  • Venus Remedies secures regulatory approvals for three key oncology drugs in Ukraine
  • Venus Remedies obtains marketing authorizations for essential oncology drugs in Ukraine
  • Venus Remedies awarded its first incentive of Rs.7.50 crore under PLI scheme
  • Venus Remedies Secures Multiple Marketing Authorizations for Key Pharmaceuticals in Ukraine
  • Venus Remedies Ltd receives GMP certification from Libya
  • Venus Remedies Ltd announces successful receipt of new marketing authorization for DOCETAXEL and GEMCITABINE
  • Venus Remedies achieves Marketing Authorizations for Docetaxel in Israel and Cytarabine in Colombia
  • Venus Remedies' R3SET Takes Strategic Leap into Wellness with Holistic Health Innovations
  • Venus Remedies successfully obtains 3 new Marketing Authorizations for Enoxaparin from Bahrain
  • Venus Remedies consolidates global presence with marketing approvals from Philippines, Saudi Arabia for three drugs
  • Venus Remedies granted Market Authorizations in Saudi Arabia and Philippines
  • Venus Remedies consolidates in ASEAN, gets marketing approval for six chemotherapy drugs from the Philippines
  • Venus Remedies Ltd consolidated Q1FY24 net profit declines to Rs. 1.18 crore
  • Venus Remedies oncology wing product registrations go up to 506 with marketing approvals from four more countries
  • Venus Remedies takes its fight against AMR to next level, joins India AMR Innovation Hub
  • Venus Remedies awarded Saudi GMP approval for all its Production Facilities at Baddi
  • Venus Remedies gets marketing approval for cancer drugs from Uzbekistan, Palestine

Latest Post

  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024